NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
NLS Pharmaceutics AG (NASDAQ: NLSP)
NLSP Technical Analysis
5
As on 25th Apr 2025 NLSP STOCK Price closed @ 1.50 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.30 & Strong Buy for SHORT-TERM with Stoploss of 0.52 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NLSPSTOCK Price
Open | 1.46 | Change | Price | % |
High | 1.53 | 1 Day | 0.00 | 0.00 |
Low | 1.46 | 1 Week | 0.00 | 0.00 |
Close | 1.50 | 1 Month | -0.03 | -1.96 |
Volume | 11522 | 1 Year | 0.94 | 167.86 |
52 Week High 5.30 | 52 Week Low 0.11 |
NASDAQ USA Most Active Stocks
AMRS | 0.14 | 100.00% |
GNLN | 0.01 | -50.00% |
AGMH | 0.05 | 25.00% |
OMEX | 1.51 | 77.65% |
NVDA | 111.01 | 4.30% |
WW | 0.40 | 166.67% |
TSLA | 284.95 | 9.80% |
INTC | 20.05 | -6.70% |
OPEN | 0.76 | -2.56% |
LMDX | 0.02 | 0.00% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
NLSP Daily Charts |
NLSP Intraday Charts |
Whats New @ Bazaartrend |
NLSP Free Analysis |
|
NLSP Important Levels Intraday
RESISTANCE | 1.63 |
RESISTANCE | 1.59 |
RESISTANCE | 1.56 |
RESISTANCE | 1.54 |
SUPPORT | 1.46 |
SUPPORT | 1.44 |
SUPPORT | 1.41 |
SUPPORT | 1.37 |
NLSP Forecast April 2025
4th UP Forecast | 2.17 |
3rd UP Forecast | 1.96 |
2nd UP Forecast | 1.82 |
1st UP Forecast | 1.69 |
1st DOWN Forecast | 1.31 |
2nd DOWN Forecast | 1.18 |
3rd DOWN Forecast | 1.04 |
4th DOWN Forecast | 0.83 |
NLSP Weekly Forecast
4th UP Forecast | 1.79 |
3rd UP Forecast | 1.70 |
2nd UP Forecast | 1.64 |
1st UP Forecast | 1.58 |
1st DOWN Forecast | 1.42 |
2nd DOWN Forecast | 1.36 |
3rd DOWN Forecast | 1.30 |
4th DOWN Forecast | 1.21 |
NLSP Forecast2025
4th UP Forecast | 12.75 |
3rd UP Forecast | 9.14 |
2nd UP Forecast | 6.91 |
1st UP Forecast | 4.68 |
1st DOWN Forecast | -1.68 |
2nd DOWN Forecast | -3.91 |
3rd DOWN Forecast | -6.14 |
4th DOWN Forecast | -9.75 |
NLS Pharmaceutics AG ( NASDAQ USA Symbol : NLSP )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
NLSP Other Details
Segment | EQ | |
Market Capital | 29899394.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
NLSP Address
![]() |
NLSP Latest News
NLSP Business Profile
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is based in Stans, Switzerland. Address: Alter Postplatz 2, Stans, Switzerland, 6370
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service